Lemonade, Inc. (NYSE:LMND – Get Free Report) insider Maya Prosor sold 30,000 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $50.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the insider now directly owns 29,286 shares of the company’s stock, valued at $1,464,300. This trade represents a 50.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Maya Prosor also recently made the following trade(s):
- On Monday, November 11th, Maya Prosor sold 20,000 shares of Lemonade stock. The stock was sold at an average price of $30.00, for a total value of $600,000.00.
Lemonade Trading Down 1.5 %
Shares of LMND opened at $49.16 on Thursday. Lemonade, Inc. has a 12 month low of $14.03 and a 12 month high of $53.85. The firm has a fifty day simple moving average of $24.89 and a 200 day simple moving average of $20.22. The stock has a market capitalization of $3.51 billion, a price-to-earnings ratio of -16.17 and a beta of 1.68.
Institutional Investors Weigh In On Lemonade
A number of institutional investors and hedge funds have recently made changes to their positions in LMND. Marshall Wace LLP bought a new position in shares of Lemonade in the second quarter valued at $14,181,000. General Equity Holdings LP bought a new position in shares of Lemonade in the 2nd quarter valued at about $5,198,000. FMR LLC grew its position in shares of Lemonade by 93.0% in the 3rd quarter. FMR LLC now owns 318,321 shares of the company’s stock valued at $5,249,000 after acquiring an additional 153,362 shares during the period. Millennium Management LLC increased its stake in shares of Lemonade by 388.7% during the 2nd quarter. Millennium Management LLC now owns 165,689 shares of the company’s stock worth $2,734,000 after purchasing an additional 131,784 shares during the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of Lemonade in the 3rd quarter valued at about $1,571,000. Institutional investors own 80.30% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the company. Morgan Stanley raised Lemonade from an “underweight” rating to an “equal weight” rating and raised their price target for the stock from $23.00 to $42.00 in a research report on Wednesday, November 20th. Piper Sandler raised their target price on shares of Lemonade from $25.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. BMO Capital Markets upped their price target on shares of Lemonade from $13.00 to $15.00 and gave the company an “underperform” rating in a report on Thursday, November 21st. Jefferies Financial Group lowered their price objective on shares of Lemonade from $15.00 to $14.00 and set an “underperform” rating for the company in a research report on Wednesday, October 9th. Finally, JMP Securities boosted their price objective on shares of Lemonade from $40.00 to $60.00 and gave the company a “market outperform” rating in a research report on Friday, November 22nd. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $30.43.
Get Our Latest Analysis on Lemonade
About Lemonade
Lemonade, Inc provides various insurance products through various channels in the United States, Europe, and the United Kingdom. Its insurance products include stolen or damaged property, and personal liability that protects its customers if they are responsible for an accident or damage to another person or their property.
Featured Stories
- Five stocks we like better than Lemonade
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Buy P&G Now, Before It Sets A New All-Time High
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What Are Dividend Achievers? An Introduction
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Lemonade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lemonade and related companies with MarketBeat.com's FREE daily email newsletter.